Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 68 citing Beck: Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophos.... (0.11 sec) 

What makes clinical research ethical?

- tmc.edu [PDF] 
EJ Emanuel, D Wendler, C Grady - Jama, 2000 - Am Med Assoc
Many believe that informed consent makes clinical research ethical. However,
informed consent is neither necessary nor sufficient for ethical clinical
research. Drawing on the basic philosophies underlying major codes, ...
Cited by 690 - Related articles - BL Direct - All 15 versions

Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines


RJ Gralla, D Osoba, MG Kris, P Kirkbride, PJ … - Journal of Clinical Oncology, 1999 - jco.ascopubs.org
THE GOAL OF ANTIEMETIC therapy is to prevent nausea and vomiting completely.
This goal is achieved for many patients receiving chemotherapy or radiation
therapy, and is based on clinical and basic research that has steadily ...
Cited by 514 - Related articles - BL Direct - All 14 versions

[CITATION] The continuing unethical use of placebo controls


KJ Rothman, KB Michels - The New England journal of medicine, 1994 - nejm.highwire.org
The Nuremberg Code, "the cornerstone of modern human experimentation ethics," 2
was formulated shortly after World War II in response to Nazi atrocities. The
World Health Organization adopted a version of the code in 1964 as the ...
Cited by 473 - Related articles - BL Direct - All 5 versions

Proposal for classifying the acute emetogenicity of cancer chemotherapy

- ascopubs.org [PDF] 
PJ Hesketh, MG Kris, SM Grunberg, T Beck, … - Journal of Clinical Oncology, 1997 - jco.ascopubs.org
Purpose: To propose a classification of the acute emetogenicity of
antineoplastic chemotherapy agents, and to develop an algorithm to define the
emetogenicity of combination chemotherapy regimens. Methods: A Medline ...
Cited by 388 - Related articles - BL Direct - All 7 versions

The ethics of placebo-controlled trials--a middle ground


EJ Emanuel, FG Miller - The New England journal of medicine, 2001 - nejm.highwire.org
The first placebo-controlled trial was probably conducted in 1931, when
sanocrysin was compared with distilled water for the treatment of tuberculosis.
1 Ever since then, placebo-controlled trials have been controversial, ...
Cited by 163 - Related articles - BL Direct - All 16 versions

Control of chemotherapy-induced emesis.


SM Grunberg, PJ Hesketh - The New England journal of medicine, 1993 - ncbi.nlm.nih.gov
The development of antiemetic drugs has been one of the most rewarding areas of
oncologic research, since therapeutic advances in this area can result in
immediate improvement in the quality of life for patients undergoing ...
Cited by 152 - Related articles - All 5 versions

Modification of Visceral Sensitivity and Pain in Irritable Bowel Syndrome by 5-HT< sub> 3 …


PA Goldberg, MA Kamm, P Setti-Carraro, JRM … - Digestion, 1996 - content.karger.com
Intrinsic neurons containing serotonin (5-HT) are involved in the regulation of
gastrointestinal motor function and are also thought to be important in the
modulation of visceral sensory function. We have evaluated the effect of a ...
Cited by 77 - Related articles - BL Direct - All 4 versions

An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional …


IT Jantunen, VV Kataja, TT Muhonen - European Journal of Cancer, 1997 - Elsevier
Ten years after it was demonstrated in the ferret that cisplatin-induced emesis
could be blocked by the selective 5-HT 3 receptor antagonist MDL 72222, 5-HT 3
receptor antagonists have become routine anti-emetic agents for ...
Cited by 59 - Related articles - BL Direct - All 5 versions

Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice

- alphamedpress.org
PJ Hesketh - The Oncologist, 1999 - AlphaMed Press
Significant progress has been made in recent years in developing more effective
and better tolerated means to prevent nausea and vomiting induced by cancer
chemotherapy. The most significant development has been the introduction of ...
Cited by 58 - Related articles - All 9 versions

Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to …


DR Gandara, F Roila, D Warr, MJ Edelman, EA … - Supportive Care in Cancer, 1998 - Springer
Abstract Selective antagonists to the Type 3 serotonin receptor (5HT 3 ) in
combination with corticosteroids are now considered the standard of care for the
prevention of emesis from moderately to highly emetogenic chemotherapy. ...
Cited by 53 - Related articles - BL Direct - All 3 versions


Result Page: 

1

2

3

4

5

6

7

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google